| Ytd | -10.21% | |
| 1y | 131.52% |
| Open | 28.80 | Prev Close | 28.81 | Low | 28.68 | High | 28.81 | Mkt Cap | 1.79B |
| Vol | 4.81K | Avg Vol | 705.00K | EPS | -2.81 | P/E | -10.25 | Forward P/E | 204.08 |
| Beta | 1.17 | Short Ratio | 14.73 | Inst. Own | 120.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 30.61 | 200-d Avg | 31.61 | 1yr Est | 45.82 |
STOK News
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
Goldman Sachs analyst Kevin Strang initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a
—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027——Ph
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedica
Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
BTIG analyst Thomas Shrader reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains
Stoke Therapeutics NASDAQ: STOK said its lead investigational therapy zorevunersen continued to show
Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.79 per share versus the Zacks C
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.79) per share which beat the analy
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
I initiate Stoke Therapeutics with a Buy rating, driven by late-stage progress for zorevunersen in S
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
The chair of Stoke Therapeutics disclosed selling 4,355 shares for roughly $174,000 at around $40.00
Assenagon Asset Management S.A. boosted its holdings in Stoke Therapeutics, Inc. (NASDAQ: STOK) by 3
The chief medical officer of Stoke Therapeutics disposed of 14,311 Common Stock shares for a transac
Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85,
On Wednesday, 311 stocks hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
On Thursday, 105 stocks hit new 52-week lows.